Can NuScale Power (SMR) Stock Reach $11?

NuScale Power Corporation (SMR) designs and commercializes small modular reactors (SMRs) for carbon-free baseload power. After a punishing 2026 that has erased roughly two-thirds of its market value, the question on investors' minds is whether the stock can recover toward a stock price target of $11.

Key Takeaways

• The $11 central target is a rounded version of the roughly $10.73 arithmetic mean of current analyst price targets (about 18 analysts), a range that spans from $4 to $20.
• With shares near $5.62, reaching $11 would require an upside of roughly 96% — a very large move that effectively implies a near-doubling of the stock.
• The analyst range is unusually wide ($4 to $20), reflecting deep disagreement between bulls focused on the company's pipeline and bears focused on execution, dilution, and absent revenue.
• Key supports include NuScale's regulatory approval status, the ENTRA1–Tennessee Valley Authority (TVA) partnership for up to 6 gigawatts (GW), a Doosan Enerbility manufacturing agreement, and roughly $1.9 billion in cash.
• Principal risks include near-zero revenue, recurring net losses, shareholder dilution, repeated price-target cuts and downgrades, and legal/regulatory scrutiny over project delays.
• The overall consensus rating is "Hold," and analysts have been trimming targets throughout 2026 as commercialization has moved more slowly than expected.
• For more detail on the company's Major News, Today's Price Move, Forecast, and Earnings, explore these dedicated pages for context beyond this article.
• For a data-driven complement to analyst research, explore Trending AI Robots to see how AI-driven strategies are monitoring names like SMR.

Analyst Price Targets and Consensus View

The central $11 target reflects a rounded arithmetic mean of current analyst price targets of approximately $10.73, based on roughly 18 analysts tracked by S&P Global. The range is extraordinarily wide — from $4 to $20 — which underscores how divided the Street remains. The prevailing rating is "Hold," with a minority of bulls offset by a growing cluster of sells.

Recent actions have leaned bearish. In October 2026, Barclays downgraded SMR to Underweight with a $5 target, Citigroup cut its target to $4 (Sell), Truist lowered its target to $8 (Hold), RBC Capital moved to $7 (Sector Perform), and B. Riley trimmed its target to $10 while keeping a Buy. UBS downgraded to Sell with a $6 target in September. On the optimistic side, Canaccord Genuity and Cantor Fitzgerald have maintained Buy/Overweight ratings with targets near $15–$20, arguing the company's technology and pipeline justify a premium.

The reasoning behind the split is consistent: bulls emphasize NuScale's status as the only U.S. company with regulatory design approval for a small modular reactor and the transformative 6 GW ENTRA1–TVA project, while bears point to minimal revenue, heavy cash burn, and dilution. None of these figures is a guarantee of where shares will trade.

Current Market Position and Path Toward the Target

Shares closed near $5.62 in late October 2026, down roughly 64% year to date and not far above the 52-week low near $5.20 — a sharp contrast with the 52-week high of $45.54. To reach $11, the stock would need to rise approximately 96%, a very large move by any standard.

The path would require a decisive shift in the fundamental narrative. NuScale currently generates little revenue and posts consistent net losses; the investment case rests on converting a non-binding pipeline into firm, revenue-generating orders. Management has said it hopes to sign a power-purchase agreement (PPA) with TVA for the ENTRA1-backed project, which would represent the clearest catalyst for a re-rating. Absent such a milestone, the stock's negative earnings and reliance on future contracts make sustained appreciation difficult to justify on current fundamentals alone.

What Could Support a Move Toward the Target

• Regulatory moat: NuScale is the only company with U.S. Nuclear Regulatory Commission design approval for a small modular reactor, a meaningful first-mover advantage.
• ENTRA1–TVA pipeline: The partnership for up to 6 GW of capacity is the largest SMR commitment in the U.S.; a signed PPA could materially improve visibility.
• Manufacturing progress: The Doosan Enerbility agreement for reactor pressure vessel components signals movement toward actual construction capability.
• Balance sheet: Roughly $1.9 billion in cash and equivalents reduces near-term funding risk, though it came partly at the cost of shareholder dilution.
• Sector tailwinds: Rising demand for firm, carbon-free baseload power and policy support for domestic nuclear fuel continue to favor the nuclear theme.

What Could Prevent the Target From Being Reached

• Execution and revenue risk: Quarterly revenue has been negligible, and converting agreements into firm deals has been slower than analysts anticipated.
• Dilution: The use of at-the-market (ATM) equity issuance has weighed on per-share value and contributed to target cuts.
• Downgrades and sentiment: A wave of late-2026 target reductions and Sell ratings reflects weakened confidence in near-term catalysts.
• Legal and regulatory overhang: Securities-related inquiries tied to project delays have added a sentiment and litigation risk layer.
• Valuation and rates: As a long-duration, pre-revenue growth asset, NuScale is sensitive to higher interest rates and rotation away from speculative names.

Technical Levels and Market Structure

The technical picture remains defensive. SMR trades below its 50-day moving average (near $8.40) and its 200-day moving average (near $9.75), and it sits only a few percent above its 52-week low near $5.20. That $5.20 area is the key support level to monitor; a decisive break would open room toward new lows. On the upside, the stock faces psychological resistance around $10 and then the mean target near $11, with the wide analyst range ($4–$20) suggesting limited agreement on a durable ceiling. A sustained recovery would first require reclaiming the moving averages before any larger trend shift.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms vary. The most consequential near-term items include the next quarterly earnings report, any update on the ENTRA1–TVA PPA, further Doosan manufacturing milestones, and the pace of cash burn and ATM issuance. Investors should also watch analyst revisions, the status of legal inquiries, interest-rate moves, and any shift in sentiment toward long-duration nuclear names. None of these should be read as a forecast of a specific outcome or timing.

AI Daily Buy/Sell Signals

Beyond traditional analyst research, AI Daily Buy/Sell Signals uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, keep an eye on existing positions, and spot shifting trends more efficiently than manual screening allows. For investors tracking a volatile, catalyst-driven name like SMR, an always-on signal stream can help flag momentum shifts as they develop.

Final Assessment

The $11 target — a rounded average of roughly 18 analyst price targets that span $4 to $20 — implies a near-doubling from the current level near $5.62, a very large move that would require a fundamental breakthrough rather than a modest recovery. The strongest supports are NuScale's regulatory approval, the ENTRA1–TVA pipeline, the Doosan manufacturing agreement, and a strengthened balance sheet. The principal obstacles are near-zero revenue, persistent losses, dilution, repeated downgrades, and legal overhang. The wide analyst range reflects genuine uncertainty about whether and when the pipeline converts into contracted revenue. A signed TVA power-purchase agreement and a stabilization of the stock's technical structure are the clearest signposts to watch next.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations